Journal article
A Window Study of Acalabrutinib & Rituximab, Followed By Chemotherapy & Autograft (ASCT) in Fit Patients with Treatment Naive Mantle Cell Lymphoma (MCL): First Report of the Investigator-Initiated Australasian Leukaemia & Lymphoma Group NHL33 'Wamm' Trial
Eliza A Hawkes, Sze Ting Lee, Leonid Churilov, Tasman Armytage, Georgina Hodges, Chan Yoon Cheah, Joel Wight, Nicole Wong Doo, Matthew Ku, Stephen S Opat, Tara Cochrane, Greg Hapgood, Hui-Peng Lee, Rishu Agarwal, Wendi Lin, Minu Koshy, Mannu Walia, Liudmyla Olenko, Paul Sung-Hao Yeh, Bianca Devitt Show all
BLOOD | ELSEVIER | Published : 2023
Abstract
Introduction Bruton's tyrosine kinase inhibitors (BTKi) have improved 1 st line therapy efficacy in elderly (Wang NEJM 2022) and young, fit, MCL-the latter with intermittent dosing during RCHOP in an alternating RCHOP/cytarabine-based regimen (Dreyling Blood 2022). However direct combination of BTKi & intensive chemo is toxic in DLBCL studies. (Kuruvilla Haematol Oncol 2017). The highly selective BTKi, acalabrutinib (A), has proven efficacy and tolerability in relapsed MCL (Wang Lancet 2018). RDHAOx chemotherapy (rituximab, dexamethasone, cytarabine, oxaliplatin) prior to ASCT provides a complete response (CR) rate of 77% and favourable toxicity compared to many induction regi..
View full abstract